SC-N143, A prospective cohort study to define infectious burden, the seroprevalence of vaccine preventable pathogens and immune recovery in the first year following completion of therapy in patients with acute lymphoblastic leukemia (ALL)
SC-N143, Vaccine Immune Recovery After Leukemia
What is the goal of the study?
Aim 1: To determine the overall infection incidence rate within the first year following completion of therapy for acute lymphoblastic leukemia. Aim 2a: To describe seroprevalence for pneumococcus, varicella, and measles at 3, 6, and 12 months following completion of therapy in patients with ALL Aim 2b: To describe B and T lymphocyte subset recovery, specifically CD4+ Tfh, using PMBCs at 3, 6 and 12 months following completion of ALL.
Who can participate in the study?
Please contact the study team listed below to learn more.